CAR-T B-Cell NHL Global Market Forecast

  • ID: 4375350
  • Drug Pipelines
  • Region: Global
  • 177 Pages
  • iOnco-analytics
1 of 4
Commercial Assessment of New CAR-T Therapies in Relapsed/Refractory Non-Hodgkin Lymphomas (B-cell types)

FEATURED COMPANIES

  • Axi-Cel
  • Juno
  • Kite Pharma
  • Novartis
  • MORE

This report consists of a detailed Executive presentation (~177 slides) and MS-Excel workbook forecasting the commercial potential ($ 000s) of novel CAR-T therapies (per competitor) in adult r/r NHL B-cell type lymphomas (new cases) across 9 major Western markets to 2030. A patient-based flow methodology has been devised where two possible intervention scenarios for CAR-T introduction are visualised so that the optimum product positioning can be assessed. In addition, an up-to-date review of NHL disease background, epidemiology, current and future treatments is presented along with a comprehensive review of the CAR-T NHL competitive landscape. Pricing, cost effectiveness, manufacturing and logistical considerations are also discussed. All assumptions are clearly provided.

Non-Hodgkin Lymphomas (NHLs) are a heterogeneous group of malignancies which have a wide range of histological appearances and clinical features. They are divided into two prognostic groups: Indolent lymphomas and Aggressive lymphomas. Of the B-cell type aggressive forms, Diffuse large B-cell lymphoma (DLBCL) and Follicular lymphoma (FL) are common types accounting for around 65% of cases (WHO figures). DLBCL is most common in people over 50 and has a current 5-year survival rate around 62%. It is estimated that approximately 26,000 people will be diagnosed with DLBCL in the United States in 2016.

There are many treatment strategies for NHLs including radiation therapy, chemotherapy (e.g. CHOP, CVP) and various combinations with rituximab or other anti-CD20 mAbs. Stem cell or bone marrow transplant is an also option for certain patients. There is a high unmet need within the relapsing/refractory subset of patients who have an extremely poor prognosis.

New treatments for NHL under investigation include the checkpoint inhibitors (PD-1 and PD-L1), therapeutic vaccines (CDX-301, SD101) and CAR-T cell therapies: Axi-Cel/KTE-C19, JCAR017 and CTL019 (tisagenlecluecel-T) developed by Kite Pharma, Juno Therapeutics and Novartis Pharmaceuticals respectively. Kite’s KTE-C19 has already been filed in the US for DLBCL with Novartis and Juno expected to follow closely in both US and the EU.

*** Please allow up to 48 hours for this product to be dispatched ***

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Axi-Cel
  • Juno
  • Kite Pharma
  • Novartis
  • MORE
  • Executive summary
  • Author’s note
  • CAR-T treatment for r/r B-cell NHLs – commercial model: key outputs
  • CAR-T eligible NHL patients/line of therapy to 2030 (45-74 yrs) Global
  • CAR-T eligible NHL patients/line of therapy to 2030 (45-74 yrs) USA only
  • CAR-T eligible NHL patients/line of therapy to 2030 (45-74 yrs) M5EU only
  • CAR-T treated NHL patients/line of therapy to 2030 (45-74 yrs) Global
  • CAR-T treated NHL patients/line of therapy to 2030 (45-74 yrs) USA only
  • CAR-T treated NHL patients/line of therapy to 2030 (45-74 yrs) M5EU only
  • CAR-T cell therapy: projected NHL revenue forecast per scenario ($000s) (45-74 yrs) to 2030 (Global)
  • CAR-T cell therapy: projected NHL revenue forecast per scenario ($000s) (45-74 yrs) to 2030 (USA only)
  • CAR-T cell therapy: projected NHL revenue forecast per scenario ($000s) (45-74 yrs) to 2030 (M5EU only)
  • CAR-T cell therapy: projected NHL revenue forecast per competitor ($000s) (45-74 yrs) to 2030 (Global)
  • CAR-T treatment for r/r B-cell NHLs – commercial model: key outputs
  • CAR-T eligible NHL patients/line of therapy to 2030 (all ages) Global
  • CAR-T eligible NHL patients/line of therapy to 2030 (all ages) USA only
  • CAR-T eligible NHL patients/line of therapy to 2030 (all ages) M5EU only
  • CAR-T treated NHL patients/line of therapy to 2030 (all ages) Global
  • CAR-T treated NHL patients/line of therapy to 2030 (all ages) USA only
  • CAR-T treated NHL patients/line of therapy to 2030 (all ages) M5EU only
  • CAR-T cell therapy: projected NHL revenue forecast per scenario ($000s) (all ages) to 2030 (Global)
  • CAR-T cell therapy: projected NHL revenue forecast per scenario ($000s) (all ages) to 2030 (USA only)
  • CAR-T cell therapy: projected NHL revenue forecast per scenario ($000s) (all ages) to 2030 (M5EU only)
  • CAR-T cell therapy: projected NHL revenue forecast per competitor ($000s) (all ages) to 2030 (Global)
  • Non-Hodgkin Lymphoma (NHL): disease background and epidemiology
  • Non-Hodgkin lymphoma (NHL): classification
  • NHL: Relative frequencies of B cell lymphoma subtypes in adults
  • Diffuse Large B cell Lymphoma (DLBCL)
  • Follicular Lymphoma (FL)
  • NHL: World incidence and mortality rates, region and sex
  • NHL: overall statistics in the US
  • NHL: new cases and deaths in US
  • NHL: cases by stage
  • NHL: NHL incidence vs other cancer types in US 2017
  • NHL: US Incidence and death rate by age
  • NHL: US incidence by sex and race/ethnicity
  • NHL: US new cases and deaths 1975-2014 and five-year survival
  • NHL: overall statistics in the UK
  • NHL: UK new cases and incidence rates by country (2014)
  • NHL: UK new cases and incidence rate by age and sex (2012-2014)
  • NHL: UK incidence and mortality rate over time
  • NHL: UK number of deaths and mortality rate by country and sex (2014)
  • NHL: UK incidence by stage at diagnosis
  • NHL: UK incidence projections to 2035
  • NHL: UK prevalence statistics
  • NHL: UK mortality projections to 2035
  • NHL: European incidence by sex (2012)
  • NHL: European mortality by sex (2012)
  • NHL: Prevalence in Europe, both sexes, 2012
  • NHL: Prevalence in Europe, by sex 2012
  • NHL: Canada - incidence and mortality statistics, 2012
  • NHL: Canada - prevalence statistics, 2012
  • NHL: Japan - incidence and mortality statistics, 2012
  • NHL: Japan - prevalence statistics, 2012
  • NHL: Australia - incidence and mortality statistics, 2012
  • NHL: Australia - prevalence statistics, 2012
  • NHL: Incidence and mortality comparison - US, Canada, Europe, Japan, Australia in 2012
  • Non-Hodgkin Lymphoma - disease classification and diagnosis
  • Further classification of NHL
  • NHL: symptoms and diagnosis
  • NHL: International Prognostic Index
  • Non-Hodgkin Lymphoma – treatment
  • NHL: Treatment (Adults)
  • NHL: Treatment for relapsed disease (Adults)
  • NHL: Treatment (Adults)
  • NHL: Treatment for relapsed disease (childhood)
  • Immunotherapy for NHL
  • Checkpoint inhibitors
  • Monoclonal antibodies
  • Therapeutic vaccines
  • Adoptive T-cell therapies
  • NHL: The unmet need for DLBCL
  • SCHOLAR-1 DLBCL outcomes study
  • Novel treatments for NHL: CAR-T cell therapy
  • Chimeric Antigen Receptor T cells (CAR-T): overview
  • Chimeric Antigen Receptor T cells (CAR-T): second generation
  • Chimeric Antigen Receptor T cells (CAR-T): antigen selection
  • CAR-T cell therapy: potential issues and challenges
  • CAR-T cell therapy for NHL: pipeline analysis methodology
  • CAR-T cell therapy for NHL: pipeline analysis findings
  • Pipeline analysis table: industry sponsored CAR-T studies for NHL
  • Kite Pharma: Axi-Cel (KTE-C19)
  • Kite Pharma: CAR R&D pipeline, July 2017
  • Axi-Cel (KTE-C19): ZUMA-1 study design
  • Axi-Cel (KTE-C19): ZUMA-1 - Phase I data
  • Axi-Cel (KTE-C19): ZUMA-1 - pivotal Phase 2 data
  • Axi-Cel (KTE-C19): ZUMA-1 - summary of data
  • Axi-Cel (KTE-C19): National Cancer Institute (NCI) studies
  • Axi-Cel (KTE-C19): durable complete remission in aggressive NHL
  • Axi-Cel (KTE-C19) in combination with checkpoint inhibitor atezolizumab
  • Axi-Cel (KTE-C19): manufacturing process
  • Axi-Cel (KTE-C19): the path to commercialization
  • Axi-Cel (KTE-C19): Joint ventures and infrastructure building
  • Juno Therapeutics Inc, Celgene Corporation: JCAR017
  • Juno Therapeutics Inc - CAR and TCR R&D pipeline
  • Juno/JCAR017: Lead candidate
  • Juno/JCAR017: Phase I (TRANSCEND) design
  • Juno/JCAR017: Phase I (TRANSCEND) data
  • Juno/JCAR017: Summary
  • Other NHL Juno data
  • Juno/JCAR014: Phase I/II design
  • Juno/ JCAR014: Phase I - published data
  • Juno/JCAR014: further Phase I/II data
  • Juno/ MedImmune LLC: JCAR014 - combination study
  • Juno/MedImmune LLC: JCAR018 - Phase I design
  • Juno/JCAR017: the path to commercialization
  • Juno/JCAR017: manufacturing process
  • Novartis: CTL019 (tisagenlecluecel-T)
  • Novartis: CTL019 (tisagenlecluecel-T) – milestones
  • NVS/CTL019 for DLBCL - Phase II design (JULIET)
  • NVS/CTL019 for DLBCL - Phase II data
  • NVS/CTL019 for DLBCL - duration of response (JULIET)
  • NVS/CTL019: the path to commercialization
  • NVS/CTL019: manufacturing process
  • Cellular Biomedicine Group Ltd: C-CAR011
  • Comparing attributes of main CAR-T candidates for the NHL indication
  • Comparing clinical data of main CAR-T candidates for the NHL indication
  • Modelling commercial potential of CAR-T cell therapies
  • Modelling rationale: CAR-T therapy
  • CAR-T cell therapy for NHLs: Target product profile
  • Modelling approach: markets modelled in this analysis
  • Modelling approach: populations
  • Modelling approach: incidence/ no of cases / indications
  • Modelling approach: patient flow/treatment scenarios
  • Modelling rationale: CAR-T treatment rates per line of therapy
  • Modelling approach: CAR-T pricing
  • Pricing CAR-T therapies: comparable analysis
  • Pricing CAR-T therapies: stakeholder comments
  • Key CAR-T clinical pipeline summary for NHL/DLBCL
  • Potential launch sequence: CAR-T for NHL (DLBCL)
  • CAR-T for NHL (DLBCL): competitor market share assumptions
  • CAR-T cell therapies for NHLs: issues and challenges
  • Model validations
  • Model caveats and limitations
  • Bibliography
  • About us
  • Disclaimer
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Axi-Cel
  • Juno
  • Kite Pharma
  • Novartis
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll